e-learning
resources
Vienna 2012
Tuesday, 04.09.2012
Idiopathic pulmonary fibrosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF)
J. Chien, L. Shao, S. Lyman, J. Adamkewicz, V. Smith, T. O‘Riordan (Seattle, United States Of America)
Source:
Annual Congress 2012 - Idiopathic pulmonary fibrosis
Session:
Idiopathic pulmonary fibrosis
Session type:
Poster Discussion
Number:
3153
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Chien, L. Shao, S. Lyman, J. Adamkewicz, V. Smith, T. O‘Riordan (Seattle, United States Of America). Elevated serum LOXL2 levels are associated with rapid disease progression in idiopathic pulmonary fibrosis (IPF). Eur Respir J 2012; 40: Suppl. 56, 3153
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
IL8 as a marker of severity of disease progression in patients with idiopathic pulmonary fibrosis (IPF)
Source: Eur Respir J 2007; 30: Suppl. 51, 373s
Year: 2007
Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity
Source: Eur Respir J 2005; 26: Suppl. 49, 21s
Year: 2005
Serum interleukin 6 levels predict disease progression in scleroderma-associated interstitial lung disease
Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease
Year: 2010
Plasma levels of circulating cell-free DNA are increased in idiopathic pulmonary fibrosis but do not correlate with disease severity
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
Plasma mitochondrial DNA as a biomarker of disease progression in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Novel insights in the basic and translational research on idiopathic interstitial pneumonias
Year: 2018
Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013
Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2015 – IPF pathogenesis
Year: 2015
Plasma protein signature of idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making
Year: 2013
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression
Source: Eur Respir J 2014; 43: 1430-1438
Year: 2014
Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Endotrophin is related to disease progression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Year: 2020
The circulating metabolome in idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia
Year: 2019
Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis
Source: International Congress 2015 – Interstitial lung diseases II
Year: 2015
Serum KL-6 as a multidimensional biomarker in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD).
Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis
Year: 2020
Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)?
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005
MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 3 (1) 00074-2016; 10.1183/23120541.00074-2016
Year: 2017
Late Breaking Abstract - Increased serum levels of YKL-40 in male smoking chronic obstructive pulmonary disease patients associated with altered miRNA levels in alveolar macrophages
Source: Virtual Congress 2020 – New biomarkers for management of obstructive diseases
Year: 2020
Down-regulation of inhibitory of growth family member 4(ING4) in idiopathic pulmonary fibrosis (IPF). Correlation with disease progression
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept